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PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Particle size and activation threshold: a new dimension of danger signaling
Lorna Rettig,1 Sebastian P. Haen,1 Anne Greet Bittermann,2 Lotta von Boehmer,1 Alessandra Curioni,1 Stefanie D. Kra¨mer,3
Alexander Knuth,1 and Steve Pascolo1
1Department of Oncology, University Hospital of Zu¨rich, Zu¨rich; 2Center for Microscopy and Image Analysis, University of Zu¨rich, Zu¨rich; and 3Department of
Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH), Zu¨rich, Switzerland
Previous studies have shown that single-
stranded RNA (ssRNA) mixed with prota-
mine forms particles and activates im-
mune cells through Toll-like receptors
(TLRs). We have found that the size of
protamine-RNA particles generated de-
pends on the electrolyte content when
mixing the 2 components. Moreover, we
have evidenced that (1) nanometric par-
ticles induce production of interferon-,
whereas (2) micrometric particles mainly
induce production of tumor necrosis fac-
tor- (TNF-) in human immune cells. We
found that the mechanisms underlying
these observations are (1) nanoparticles
but not microparticles are selectively
phagocytosed by plasmacytoid dendritic
cells (pDCs), which produce interferon-
and (2) monocytes that produce TNF-
have a higher activation threshold than
that of pDCs. Thus, at the same time as
sensing pathogen-associated molecular
patterns such as ssRNA, the immune
system distinguishes the size of the asso-
ciated structure in such a way as to
trigger the adapted antivirus (nanomet-
ric) or antibacterial/antifungal (micromet-
ric) immune response. Our results intro-
duce a new dimension in danger
signaling—how size qualitatively affects
innate response. (Blood. 2010;115(22):
4533-4541)
Introduction
The innate immune system is capable of sensing invading pathogens
and abnormal cells by the detection of “danger signals.” Danger signals
are molecules originating specifically from invaders and disturbed cell
metabolism. Studies show 3 forms of nucleic acid are recognized by the
mammalian immune system as danger signals: DNAcontaining unmeth-
ylated CG sequences (CpG), unmodified single-stranded RNA
(ssRNA), and double-stranded RNA (dsRNA). Such foreign nucleic
acids mislocalized in the intracellular compartments are recognized by
endosome-resident Toll-like receptor 9 (TLR9), TLR-7, TLR-8, and
TLR-3, respectively (reviewed in Takeda et al1). When engaged, those
receptors deliver an activation signal to the cell. Subsequently, cytokines
and costimulation molecules are produced and certain homing and
chemokine receptors are up-regulated.
The first identified nucleic acid danger signal, dsRNA, was
validated as an antitumor immunotherapeutic compound in mice in
the 1960s and further tested as an immunostimulating compound in
cancer patients in the 1970s.2,3 However, low clinical efficacy as
well as toxicity issues precluded the further evaluation of dsRNA
for antitumor immunotherapy. Nevertheless, dsRNA is nowadays
available in the form of a less toxic, interrupted polyinosinic-
polycytidylic acid duplex (Ampligen; Hemispherx Biopharma) and
is used for treating chronic fatigue.
Although unmethylated CpG-containing DNA is the most
recently identified nucleic acid danger signal,4 it is the most
thoroughly studied and clinically evaluated up to now. One relevant
but unexplained feature of CpG oligodeoxynucleotides (ODNs) is
that they trigger a sequence-dependent immunostimulation pro-
file5: ODN of the “A” class mostly activate plasmacytoid dendritic
cells (pDCs) and induce the production of interferon-, whereas those of
the “B” class mostly activate B cells and induce the production of
TNF-. The “C” class CpG ODNs activate both pDCs and B cells,
stimulating the production of both of these cytokines.
The ssRNA molecules were found to be mildly immunostimulating
in the 1960s.6 Using rabbit kidney cultures, Billiau et al showed in 1969
that ssRNA mixed with polybasic substances such as protamine
activates the interferon pathway and thereby induces protection against
vesicular stomatitis virus or Semliki Forest virus.7 More recently we and
others have shown that stabilized ssRNA(phosphorothioate oligoribonu-
cleotide or mRNA premixed with protamine) strongly activates human
and mouse immune cells through TLRs.8-10 The identification of TLR-7
and TLR-8 as the receptors for ssRNA has boosted the study and
development of this danger signal.11-13 No precise sequence motif is
needed in the RNA to stimulate TLR-7 and TLR-8; however, U-
residues, and to a lesser extent G-residues, are most potent.11,14,15 Up to
now, the specific immunostimulation profile triggered by ssRNAhas not
been investigated. Here, we present the finding that when using
protamine to formulate RNA, we can generate nanoparticles (diameter
 220 nm) or microparticles ( 1200 nm) depending on the conditions
of formulation. Most importantly, we show that nano- and micropar-
ticles induce qualitatively different innate immune responses. Our data
introduce the new concept that not only the nature of the danger signal
but also its form, in either nano- or microstructures, determines the type
of innate immunity that is triggered.
Methods
Oligonucleotides
RNA oligonucleotides were all nonmodified and nonphosphorylated.
Sequences (5 to 3) are as follows: U-rich (21m) AGUGUUAUUCU-
UGUAUGGUUG; RNA18 AGUGUUAUUCUUGUAUGG; U-rich (16m)
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GUGUUAUUCUUGUAUG; U-rich (14m) GUUAUUCUUGUAUG; U-
rich (12m) GUUAUUCUUGUA; U-rich (10m) GUUAUUCUUG; A-rich
(12m) GAAAAACAAGAA; C-rich (12m) GCCACCCCCGCA; G-rich
(12m) GGGAGGCGGAGA; U-rich (12m) GUUAUUCUUGUA; Purine
(12m) AGAGAGAGAGAG; and Pyrimidine (12m) CUCUCUCUCUCU.
CpG 1826 ODN is fully phosphorothioate. All oligonucleotides were
produced by Thermo or by Microsynth.
Preparation and physical analysis of protamine-RNA particles
Five micrograms of RNA were mixed with the indicated amount of
protamine (Valeant), at the indicated concentration in the indicated solution.
One milliliter of phosphate-buffered saline (PBS, 10mM phosphate,
138mM NaCl, [pH 7.4]) was added, and the size distribution of the
protamine-RNA complexes was characterized by dynamic light scattering
with a Zetasizer 3000HSA (Malvern). After the measurement, the prepara-
tion was further diluted with 1 mL of PBS and subjected to electrophoretic
light scattering measurement, also using a Zetasizer, to determine the
zetapotential of the complexes. Data were analyzed using the built-in DTS
software. For electron microscopy the above-described components were
mixed, and a 10-L aliquot was allowed to settle for 1 minute onto Formvar
and carbon-coated copper grids, which had been freshly glow discharged.
Excess fluid was blotted. For transmission electron microscopy, grids were
stained with 2% Uranylacetat in distilled water for 3  15 seconds. Grids
were then blotted and allowed to air dry before imaging at 80 kV in a
Phillips CM 208 transmission electron microscope. For scanning electron
microscopy the grids were washed twice in distilled water. After blotting
and air drying, grids were mounted, sputter-coated with 4 nm platinum, and
imaged in a Zeiss Supra 50 VP Scanning Electron Microscope at 4 kV in the
secondary electron mode.
Preparation, isolation, and culture of human PBMCs
Human peripheral blood mononuclear cells (PBMCs) were isolated from
the blood of different donors by Ficoll density gradient centrifugation (PAA
Laboratories). After washing in PBS, cells were resuspended at 1 million/
200 L of complete medium (RPMI 1640, 10% fetal calf serum, 2mM
L-Glutamine, 10 g/mL streptomycin, 10 U/mL penicillin). Cells were
distributed in 96-well plates (200 L/well) containing stimulating RNA
(2 g of RNA in 2 L) complexed with protamine (2 g of protamine in
2 L) or CpG DNA (2 g) or polyinosinic-polycytidylic acid (2 g;
Invitrogen) or R848 (1 g; Alexis Biochemicals).
Cytokine measurement
After 24 hours of incubation at 37°C, the amount of cytokine in 20 L of
supernatant was quantified using enzyme-linked immunosorbent assay
(ELISA) kits for interferon- (Bender) or TNF- (Abazyme) or using the
Multiplex Kit (Bio-Rad) following the instructions of the manufacturer.
Cell staining
Cells were incubated with fluorescent nanospheres (Molecular Probes) for
4 hours then stained for 30 minutes in the dark at 4°C with allophycocyanin
(APC)–labeled CD11c (BD PharMingen) or APC-labeled anti–blood den-
dritic cell antigen-2 (BDCA-2; Miltenyi Biotec) monoclonal antibodies.
For intracellular staining of interferon-, fresh human PBMCs were
incubated for 6 hours with protamine-RNA particles. Cells were permeabil-
ized and fixed (Cytofix/Cytoperm kit; BD PharMingen), according to the
manufacturer’s instructions, before being stained with fluorescein isothio-
cyanate-labeled anti–interferon- antibody (BD PharMingen) and APC-
labeled anti–BDCA-2 antibody.
Generation of mouse dendritic cells
All animal experiments were approved by the University Hospital of
Zu¨rich. Bone marrow–derived dendritic cells were obtained by flushing the
bones of the hind leg of 6- to 12-week-old C57BL/6 (Charles River
Laboratories) and TLR7/ mice (TLR-7 knockout [KO] mice), kindly
provided by Dr Karl Lang (Institute of Experimental Immunology, Univer-
sity Hospital of Zu¨rich) with Iscove modified Dulbecco medium (PAN
Biotech). Cells were then cultured for 6 days in Iscove modified Dulbecco
medium with 10% heat-inactivated fetal calf serum (both from PAN
Biotech), 2mM L-Glutamine (BioWhittaker), 10 g/mL streptomycin,
10 U/mL penicillin (PEN-STREP; BioWhittaker) and granulocyte-
macrophage colony-stimulating factor (4000 ng/mL final concentration) in
Petri dishes at a concentration of 0.5  106 cells/mL. Dendritic cells were
replated on day 6 and used for experiments on day 7.
Results
The size of protamine-RNA particles depends on formulation
conditions
Being cationic, protamine spontaneously associates with anionic
RNA generating a turbid suspension immediately upon mixing. We
have previously shown10 that particles in such a solution are large
heterogenous complexes of several micrometers. These poorly
defined structures are difficult to qualify as a pharmaceutical
product; they precipitate quickly and spontaneously and are
difficult to take up and deliver through a syringe. We now observed
that the electrolyte content in RNA and protamine is critical in
generating precisely sized, homogenous particles. By dissolving
RNA pellets at 1 mg/mL in pure water and diluting Protamine 5000
(pharmaceutical protamine used as an anti–heparin drug) from
14 to 1 mg/mL in pure water, we generated homogenous nanopar-
ticles upon mixing, as detected by dynamic light scattering (Figure
1A) or transmission electron microscopy (air drying of nanopar-
ticles on microscopy grids leads to clustering; however, the
particles are dispersed in solution; Figure 1D). Thus, the electro-
lytes present in the solutions of RNA and protamine influence the
structure of the resulting protamine-RNA complexes. The size of
the RNA does not have much impact on this phenomenon: from
18 mer oligonucleotides (Figure 1A,D) up to long RNA of a few
hundred bases (Figure 1B) can be used to form nanoparticles
averaging 220 nm. Longer RNA, however, tends to generate
slightly more heterogenous particles (from 100 to 600 nm) than
oligonucleotides (compare Figure 1A to B). Particles of less than
500 nm remain polydispersed in solution and do not precipitate
spontaneously. However, they can be pelleted by centrifugation.
Introducing electrolytes in the 1-mg/mL single-component solu-
tions, for example by diluting the RNA and Protamine 5000 in
Ringer lactate solution, results in the production of larger protamine-
RNA particles (Figure 1C top, E). These particles form a pellet
within minutes when the reaction tube is on the bench. Increasing
the protamine to RNA ratio produces a slight reduction of the size
of the microcomplexes (Figure 1C) but does not affect the size of
the nanocomplexes (Figure 1A).
By diluting RNA and Protamine 5000 to a final concentration of
1 mg/mL using solutions containing various salt concentrations, we
can generate protamine-RNA nanoparticles of different sizes as
shown in Figure 1F. The higher the NaCl concentration in RNA and
protamine, the larger the generated protamine-RNA particles. The
concentration of protamine and RNA before mixing also affects the
size of the particles as shown in Table 1. The minimum possible
size of the protamine-RNA particles was approximately 220 nm.
This was obtained using Protamine 5000 diluted 14 times in water
(final concentration  1 mg/mL) and RNA at 1 mg/mL in water.
Further dilution of the 2 compounds with water did not result in any
reduction in the size of the particles (Table 1). However, when
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protamine and RNA were in Ringer lactate solution, lowering their
concentrations reduced the size of the particles: approximately
1250 nm when both components were at 1 mg/mL versus approxi-
mately 550 nm when they were at 0.25 mg/mL.
Mixing protamine and RNA at a 1:1 mass ratio generated
particles with a slightly positive surface charge (  7 mV
zetapotential; Figure 1A). Higher amounts of protamine versus
RNA increased the surface charge, whereas lower amounts of
protamine versus RNA (1:2 protamine to RNA in mass) resulted in
negatively charged particles. The same results were observed for
nano- and microparticles. A surface charge of near neutrality is
known to be optimal for particle stability, inocuity, and bioavailabil-
ity.16 Thus we performed all subsequent immunostimulating experi-
ments using a 1:1 protamine-RNA ratio.
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Figure 1. The size of protamine-RNA complexes depends on the ionic conditions of formulation. An 18-residue RNA (RNA18) oligonucleotide (A,C-F) or mRNA coding
enhanced green fluorescent protein (B) were diluted to 1 mg/mL using water (A-B,D) or Ringer lactate solution (C,E) and mixed at indicated mass ratios (A,C) or at 1:1 mass
ratios (B,D-F) with Protamine 5000 diluted to 1 mg/mL using water (A-B,D) or Ringer lactate solution (C,E). The size of the particles (A, left, B-C) was assessed by dynamic light
scattering (the number shown in each graphic indicates the average hydrodynamic diameter) and electron microscopy (transmission in panel D and scanning in panel E). Data
shown are representative of 10 independent experiments. The zetapotentials of the nanoparticles (A right) are measured using a Zetasizer (Malvern). (F) A summary of the
results from dynamic light scattering measurements of particles produced with protamine and RNA diluted to 1 mg/mL using different solutions of varying ionic strength. Each
formulation was repeated 3 times and measured. Error bars indicate the standard variation within those triplicate experiments.
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The size of protamine-RNA particles influences their
immunostimulating profile
Using total human PBMCs prepared from healthy donors, we
compared the immunostimulating capacity of protamine-RNA
particles of 220 nm, approximately 500 nm, and 1200 nm. An
18-residue RNA oligonucleotide containing all 4 bases (RNA18)
was used. The final concentration of protamine-RNA in cell culture
was 20 g/mL (10 g/mL protamine and 10 g/mL RNA). As
shown in Figure 2, the smaller the particles, the more they triggered
the production of interferon- (Figure 2A). In contrast, the larger
the particles were the more they triggered TNF- production
(Figure 2B). The resiquimod R848 induced production of high
amounts of interferon- and TNF-, whereas dsRNA was a poor
inducer of these 2 cytokines. Similar results were obtained with all
tested PBMC donors. RNA alone at 10 g/mL or protamine alone
at 10 g/mL did not induce detectable production of TNF- or
interferon- in human PBMCs. Thus, the size of the particle as
defined by the formulation conditions (mainly the electrolyte
concentration) has a direct impact on the profile of the immune
response in human cells. To analyze in more detail the differential
immunostimulation of nano- versus microparticle protamine-RNA,
we studied the production of several cytokines by human PBMCs
in culture with nano- or microparticles using Multiplex (Bio-Rad)
as a readout. As shown in supplemental Figure 2C (available on the
Blood Web site; see the Supplemental Materials link at the top of
the online article), interleukin-1 (IL-1), IL-1, interleukin-6,
monocyte chemoattractant protein-1, macrophage inhibitory protein-
1, and macrophage inhibitory protein-1 were similarly induced
by all particles and by R848. Only interleukin-10, and granulocyte
colony-stimulating factor were differentially induced; nanopar-
ticles stimulated less production of these cytokines than did either
microparticles or R848. The production of interleukin-12 (p70) was
poorly induced by nanoparticles and R848, whereas production
was best triggered by protamine-RNA microparticles.
Protamine-RNA particles are recognized by mouse TLR-7
TLR-7 and TLR-8 have previously been shown to recognize
ssRNA molecules. In mice, TLR-8 is mostly nonfunctional. Using
bone marrow–derived dendritic cells from TLR-7 KO mice, we
showed (Figure 3) that protamine-RNA nano- and microparticles
can stimulate through TLR-7: TNF- was produced by wild-type
cells stimulated with nano- and microparticle protamine-RNA,
R848, and CpG DNA, whereas TLR-7 KO cells were stimulated
only with CpG DNA but not with protamine-RNA particles or
R848. Using commercially available kits with a limit of detection
Table 1. The concentration of protamine and RNA affects particle
size
Particle size in nm
2
mg/mL
1
mg/mL
0.5
mg/mL
0.25
mg/mL
Water 575 267 274 263
25mM NaCl 492 277
75mM NaCl 1045 512
225mM NaCl 1288 869
Ringer lactate 1363 1432 926 571
Protamine 5000 was diluted 7 times ( 2 mg/mL final), 14 times ( 1 mg/mL
final), 28 times ( 0.5 mg/mL final), or 56 times (0.25 mg/mL final) with water,
25mM NaCl, 75mM NaCl, 225mM NaCl, or ringer lactate. Similarly, the RNA
oligonucleotide RNA18 was diluted to the same final concentrations as the above-
mentioned 5 solutions. Protamine and RNA were mixed at a 1:1 mass ratio.
Subsequently, the size of the particle was measured by dynamic light scattering.
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Figure 2. Protamine-RNA particles of different sizes induce different immunos-
timulation profiles. PBMCs prepared from 3 different healthy donors were incu-
bated overnight with protamine-RNA particles (ProtRNA) produced by mixing 1:1
(mass ratios) protamine and RNA (RNA18 oligonucleotide) at 1 mg/mL. Protamine
5000 and RNA were diluted with water (220 nm), 25mM NaCl solution (500 nm), or
Ringer lactate solution (1200 nm). Cells stimulated by R848 and dsRNA were used
as positive controls. The content of interferon- (A) or TNF- (B) in the supernatants
was then assessed by ELISA. The data show the mean content of cytokines for the
3 donors. Error bars indicate the observed deviation between donors. The data
shown are representative of 12 independent experiments.
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Figure 3. TLR-7 is necessary for activation of mouse dendritic cells. Bone
marrow–derived dendritic cells from wild-type (WT) and TLR-7 KO mice were
incubated overnight with RNA18, protamine, protamine-RNA particles (ProtRNA) of
220 nm or 1200 nm, CpG DNA, or R848. Thereafter cell culture supernatants were
tested by ELISA for their TNF- content. Representative results from 5 independent
experiments are shown.
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of approximately 20 pg/mL, no mouse interferon- was detected in
culture supernatants (data not shown).
Stability of protamine-RNA particles
In the described experiments (Figure 3), particles were formulated
and immediately put into cell culture. To test the stability of the
preparations, we investigated their immunostimulating capacity
after incubation at room temperature for 0, 30, and 60 minutes.
Particles were prepared at the described time points before fresh
human PBMCs were added to the wells. As shown in Figure 4A,
the immunostimulating activity of nanoparticles decreased slowly
over time. After 1 hour at room temperature, over 50% of maximal
activity was still observed. In contrast, the immunostimulating
capacity of micrometric particles dropped more quickly: nearly
90% of activity was lost within 30 minutes. This effect could reflect
the spontaneous aggregation of microparticles into a solid pellet
that may limit the availability of free particles and thus stimulation
of immune cells.
To estimate particle half-life in vivo, we studied the immunos-
timulating capacity of protamine-RNA complexes incubated in
90% human serum at 37°C. Using data from several donors, we
estimated the half-life of nanoparticles to be approximately 6 hours
Figure 4. Stability of protamine-RNA particles. Protamine 5000 diluted
14 times with water or with Ringer lactate solution was mixed 1-to-1 with
RNA18 diluted to 1 mg/mL with water or Ringer lactate solution to
generate nano- or microparticles, respectively. The formulation was
repeated at several time intervals. (A) Particles were diluted with
9 volumes of PBS and incubated at room temperature. Particles of
220 nm (B) or 1200 nm (C) were diluted with 9 volumes of fresh human
serum and incubated at 37°C. Fresh human PBMCs were added to the
particles after various incubation times as indicated. After overnight
incubation, the interferon- (for stimulation with nanoparticles) or TNF-
(for stimulation with microparticles) concentrations in the culture superna-
tants were measured by ELISA. The data shown are representative of
5 independent experiments.
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(Figure 4B), whereas the half-life of microparticles was approxi-
mately 1 hour (Figure 4C). The extended half-life of microparticles
in serum at 37°C versus in simple buffer at room temperature
( 1 hour vs 	 one-half hour) could be due to serum viscosity
preventing fast precipitation of the microparticles, leaving them
free longer to stimulate immune cells.
Deciphering the mechanisms of differential immunostimulation
by nano- and microparticles
We studied which populations of cells in PBMCs take up protamine-
RNA particles using fluorescent nanospheres of 200, 500, and
1000 nm. The results shown in Figures 5 and 6 demonstrate that
pDCs, the main producers of interferon-, efficiently phagocytose
nanoparticles but take up microparticles far less efficiently (Figure
5A). Meanwhile, CD11c cells, which make up over 85% of the
monocyte population, take up particles of all tested sizes with
similar efficiency (Figure 6A).
Although more than 90% of pDCs uptake one or (for the
majority of cells) several 200-nm particles, only 4% of pDCs cells
take up 1000-nm particles (Figure 5A). The 500-nm fluorescent
particles are phagocytosed by pDCs less efficiently than 200-nm
particles but more efficiently than 1000-nm particles. This selective
uptake depending on particle size is mirrored by the intracellular
detection of interferon- in pDCs pulsed with protamine-RNA
nano- or microparticles (Figure 5B). Thus the production of
interferon- by PBMCs incubated with nanoparticles but not
microparticles of protamine-RNA is dictated by the selective
uptake of nanoparticles by pDCs.
In contrast, phagocytosis by monocytic CD11c cells is unselec-
tive in relation to particle size (Figure 6A). Thus, the higher
production of TNF- triggered by microparticles compared with
nanoparticles is not a matter of size-selective phagocytic capacity.
The cargo of microparticles is much higher than the cargo of
nanoparticles: one 1200-nm particle contains approximately
100 times more material than one 220-nm particle. Thus, we tested
whether high load of nanoparticles could mimic the activity of
microparticles. As shown in Figure 6B, it is possible to increase the
amount of particles taken up by monocytic CD11c cells by
increasing the amount of fluorescent spheres in the cell culture.
This increase is mirrored by the TNF- production induced by high
amounts of nanoparticles (Figure 6C). At a final concentration of
20 g/mL, the production of interferon- is nearly maximal,
whereas TNF- production is low. Increasing the concentration of
220-nm particles increases TNF- production to the level observed
using microparticles (
 20 000 pg/mL). Thus the activation thresh-
old of monocytes is higher than the activation threshold of pDCs.
The former requires a greater quantity of danger signal (RNA) than
the latter for full activation.
RNA characteristics needed for optimal activation by
protamine-RNA particles
Using 500-nm nanoparticles, we studied the impact of different
RNA sequences on both TNF- and interferon- production
simultaneously in fresh human PBMCs. As shown in Figure 7A,
although a short oligonucleotide of 10 residues rich in U bases can
induce TNF- and interferon- production by PBMCs after it is
mixed with protamine, optimal activation was seen with longer
oligonucleotides. The 18 residues were enough to stimulate maxi-
mum TNF- and interferon- production: 21-residue RNA oligonu-
cleotides as well as long in vitro–transcribed RNA (data not shown)
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Figure 5. Selective phagocytosis of nanoparticles by
pDCs. Fresh human PBMCs were incubated for 4 hours
with 10 g/mL fluorescent nanospheres (A) or for 6 hours
with 20 g/mL protamine-RNA particles (B), then stained
with antibody specific for BDCA-2 and, in panel B,
anti–interferon- fluorescein isothiocyanate antibody. Cells
were analyzed by fluorescence-activated cell sorting. The
value in each quadrant indicates the percentage of cells
as a percentage of the parent gate. The data shown are
representative of 4 independent experiments.
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did not induce greater production of TNF- or interferon-. Using
oligonucleotides of 12 residues, we studied the effect of the
sequence on immunostimulation. As shown in Figure 7B,
U-residues are important for both TNF- and interferon-
production. However, a polyU RNA oligonucleotide consisting
of 12 U-residues alone barely stimulated immune cells (data not
shown). G-residues may mediate some immunostimulation: the
G-rich 12m oligonucleotide that does not contain U-residues
reproducibly induced some detectable cytokine production. How-
ever an AG purine oligonucleotide, Purine 12m, did not stimulate
human immune cells as measured by cytokine production. The
Pyrimidine 12m containing UC repeats induced weak but detect-
able TNF- and interferon- production. In summary, uraciles are
the most immunostimulating bases in RNA formulated with
protamine. G-residues may be somewhat immunostimulating,
whereas A- and C-residues are not immunostimulating.
Discussion
The capacity of ssRNA and dsRNA to induce nonspecific immune
responses including interferon production was described long before
TLRs were characterized.17 The potentiation of such phenomena by
cationic molecules such as protamine has also been previously demon-
strated.7 Having shown in 2004 that protamine-mRNA complexes
activate immune cells through receptors of the IL-1 receptor family,8 we
also tested the potential for use of those products in the clinic.18,19
However, the reagents and formulation conditions10 resulted in the
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Figure 6. The activation threshold is higher for mono-
cytes than for pDCs. Fresh human PBMCs were incu-
bated for 4 hours with 10 g/mL fluorescent spheres (A)
or 5, 10, 20, or 30 g/mL fluorescent spheres (B) stained
by APC-labeled CD11c and analyzed by fluorescence-
activated cell sorting. The dot plots presented in panel A
and analyzed in panel B were gated on monocytes on the
basis of forward-side light scatter plot (gate r9, supplemen-
tal Figure 6A, or gate r3, supplemental Figure 6B). The
value in each quadrant in panel A indicates the percent-
age of cells as a percentage of total cells. In panel B,
mean fluorescence (FL1 for 200 nm, FL2 for 500 nm, and
FL3 for 1000 nm) of CD11c cells at different particle
concentrations is shown. (C) TNF- and interferon-
present in the supernatant of fresh human PBMCs
incubated 24 hours with 15, 20, 25, 30, or 35 g/mL
protamine RNA nanoparticles (220 nm) was tested by
ELISA. The data shown are representative of 3 indepen-
dent experiments.
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production of macroscopic heterogenous aggregates (Figure 1). Here,
we show that RNA oligonucleotides can be used to formulate homog-
enous microparticles (Figure 1C). We further show that using RNA and
Protamine 5000 (the highest concentration available for pharmaceutical
protamine) both diluted to 1 mg/mL in water, we can generate homog-
enous nanoparticles (Figure 1A). One advantage of particles of less than
500 nm is that they remain polydispersed, ie they do not precipitate
spontaneously into a pellet. Thus, they are more readily usable for
clinical applications: preparation, short-term storage, uptake in a sy-
ringe, and injection. A protamine-RNA mass ratio of between 4:1 and
1:2 does not affect the size of the nanoparticles, but the ratio does affect
the resulting surface charge; it is negative at a ratio of 1:2 and slightly
positive at a 1:1 ratio or higher. It is preferable for pharmaceutical
applications that the charge of a particle is not too highly positive
because positively charged particles bind to negatively charged serum
protein and generate large aggregates that cause transient embolism in
the lung capillaries.16 Microparticles formulated with different protamine-
RNA ratios have surface charges similar to those of nanoparticles (data
not shown) but, in contrast to nanoparticles, tend to get smaller in size at
higher protamine-RNA ratios (Figure 1C). From these data, it can be
concluded that for nanoparticles, the 1:1 mass ratio of protamine-RNA
may provide complexes with ideal biophysical characteristics. As well
as exhibiting favorable immunostimulating capacities (induction of
therapeutically relevant cytokines such as interferon-) and adequate
stability and half-life of activity (Figure 4), nanoparticles also activated
pDCs from all advanced cancer patients who we tested (data not
shown). This suggests the possibility that protamine-RNA nanoparticles
could be used as an adjuvant to anticancer vaccines or as a nonspecific
immunostimulation regimen for patients suffering from advanced
malignant diseases.
Interestingly, we demonstrate here that nanoparticles and micro-
particles formed with the same RNA and same protamine at
equivalent concentrations and ratios, but in different electrolyte
conditions (low salt to form nanoparticles, isotonic salts to form
microparticles), have different immunostimulating characteristics:
nanoparticles but not microparticles induce interferon- produc-
tion in human blood cells (Figure 2A). Using fluorescent particles,
we could show (Figure 5) that pDCs selectively take up nanopar-
ticles. This size-selective characteristic of phagocytosis in pDCs
explains the observed cytokine production pattern induced in these
cells by immunostimulating nano- and microparticles.
In contrast, monocytes take up nano- and microparticles similarly
(Figure 6A). However, we could show that the threshold of activation of
monocytes is higher than the threshold of activation of pDCs (Figure
6C) in terms of the amount of danger signal needed for activation. Thus,
monocytes require a higher number of nanoparticles than microparticles
for full activation. As a result, at a concentration of 20g/mL,
microparticles of protamine-RNAbut not 220-nm nanoparticles activate
maximal TNF- production by human monocytes.
The immunomodulating capacities of danger signals have not
previously been linked to the size of the associated structure.
Purified, soluble lipopolysaccharide, CpG ODN, or dsRNA are
usually used for in vitro and in vivo experiments. However, these
danger signals are physiologically within structures of different
Figure 7. RNA sequence requirements for immunostimulation by
protamine-RNA particles. Large nanoparticles were produced using
different RNA oligonucleotides at 1 mg/mL in water, and Protamine 1000
diluted 2.5 times in water. Resulting particles were approximately 500 nm
in diameter. Fresh human PBMCs were added and cultured for 18 hours.
Supernatants were then tested for TNF- and interferon- content by
ELISA. (A) The effect of the RNA length on immunostimulation was
tested. (B) The effect of the RNA sequence on immunostimulation was
tested. Each set of experiments was repeated 3 times. Representative
data are shown.
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sizes: nanostructures (compare, viruses) in the case of dsRNA,
nano- or microstructures (compare, viruses and bacteria) in the case
of CpG DNA or ssRNA, and microstructures (compare, bacteria) in
the case of lipopolysaccharide. For CpG DNA and ssRNA, the
structure-related function of the danger signal was largely over-
looked, all focus being on how the sequence and modifications of
these nucleic acids modulates their immunostimulating activity. Of
note, however, the packaging of CpG DNA oligonucleotides in
nanoparticles using condensation on protamine20 or adsorption on
preformed polystyrene nanoparticles21 was shown to render CpG-B
sequences capable of inducing interferon- production by pDCs,
whereas soluble CpG-B sequences did not induce production. In
addition, the particularity of CpG-A sequences to induce inter-
feron- by pDCs was found to be associated with the capacity of
this oligonucleotide to spontaneously form nanoparticles.21 Accord-
ing to those studies and our present results, we suggest that the
immune system has developed the capacity to specifically react to
pathogens according to their size: pDCs selectively take up
nanoparticles (viruses), whereas monocytes require a larger amount
of danger signal than pDCs to be fully activated. In this way,
viruses (typically 5-300 nm) would trigger the potent antivirus
interferon- production, whereas bacteria (typically 500 nm to
micrometers) would trigger the potent antibacterial monocytic
activation. Both pathogens stimulate mammalian immune systems
by the same danger signals, their nucleic acids: CpG motifs and/or
unmodified RNA. However, the precise type of immune response is
dictated by both the size of the pathogen and its correlate, ie, the
amount of danger signal. Aside from pathogens, physiologic DNA-
and RNA-containing nanoparticles (exosomes) and micropar-
ticles22 are present in plasma. In particular, microparticles shed
from the plasma membranes of activated and dying cells may play
significant roles in the pathophysiology of thromboses, neuropa-
thologies, inflammation (rheumatic diseases), and cancers.23,24 In
light of our results, the particular immunostimulating activities of
different disease-associated microparticles can be re-evaluated.
In general, our data invite revision of the activities of danger
signals and associated pathogens in view of the size of the original
physiologic structure. This revision would lead to a better under-
standing of the immunomodulating capacities of pathogens or
natural nano- and micrometric structures as well as facilitating
better design of customized immunotherapy approaches.
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